ASP3291 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
97	Ulcerative colitis	2

97. Ulcerative colitis

---

Clinical trials : 2,630 /  Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01612039 (ClinicalTrials.gov)	July 2012	1/6/2012	Safety, Efficacy, and Tolerability Study of ASP3291 in Patients With Active Ulcerative Colitis	A Phase 2, Randomized, Double-Blind, Parallel, Placebo-Controlled, Proof-of-Concept Study to Assess the Efficacy, Safety, and Tolerability of ASP3291 in Patients With Active Ulcerative Colitis	Ulcerative Colitis	Drug: ASP3291;Drug: Placebo	Telsar Pharma Inc.	NULL	Completed	18 Years	65 Years	Both	112	Phase 2	United States
2	NCT01320332 (ClinicalTrials.gov)	August 2010	15/3/2011	A Study of a Single Dose of ASP3291 in Subjects With Ulcerative Colitis	A Phase 1, Randomized, Double-Blind, Placebo Controlled Study to Assess the Pharmacokinetics, Safety, and Tolerability of ASP3291 Following a Single Oral Dose in Subjects With Ulcerative Colitis	Ulcerative Colitis	Drug: ASP3291;Drug: Placebo	Telsar Pharma Inc.	NULL	Completed	18 Years	65 Years	Both	16	Phase 1	United States